NeurAxis (NYSE:NRXS) announced today that the FDA granted an expanded 510(k) clearance for its IB-Stim non-implanted nerve stimulator. IB-Stim delivers nerve stimulation for functional abdominal pain relief. The new indication expands the system’s addressable market and overall devices per patient, according to a news release. NeurAxis’ system utilizes its proprietary percutaneous electrical nerve field stimulation […]
